Bioconjugate Chemistry
Article
Semisynthetic maytansine analogues for the targeted treatment of
cancer. J. Med. Chem. 49 (14), 4392−408.
(7) Ghosh, S. S., Kao, P. M., McCue, A. W., and Chappelle, H. L.
(1990) Use of maleimide-thiol coupling chemistry for efficient
syntheses of oligonucleotide-enzyme conjugate hybridization probes.
Bioconjugate Chem. 1 (1), 71−6.
(8) (a) Liberatore, F. A., Comeau, R. D., McKearin, J. M., Pearson, D.
A., Belonga, B. Q., Brocchini, S. J., Kath, J., Phillips, T., Oswell, K., and
Lawton, R. G. (1990) Site-directed chemical modification and
crosslinking of a monoclonal antibody using equilibrium transfer
alkylating crosslink reagents. Bioconjugate Chem. 1 (1), 36−50.
(b) Godwin, A. R., Pedone, E., Choi, J. W., Shaunak, S., and
Brocchini, S. J. (2005) Conjugated biological molecules and their
preparation, Int. Patent No. WO2005007197 A2. (c) Godwin, A., and
Brocchini, S. J. (2010) Conjugated proteins and peptides, Int. Patent No.
WO 2010100430 A1.
(9) Schumacher, F. F., Sanchania, V. A., Tolner, B., Wright, Z. V. F.,
Ryan, C. P., Smith, M. E. B., Ward, J. M., Caddick, S., Kay, C. W. M.,
Aeppli, G., Chester, K. A., and Baker, J. R. (2013) Homogeneous
antibody fragment conjugation by disulfide bridging introduces
‘spinostics’. Sci. Rep. 3, 1525.
(10) Griebenow, N., Braese, S., and Dilmac, A. M. (2015)
Application of a novel small scale UV LED photochemical batch
reactor for the thiol-yne reaction. RSC Adv. 5, 54301−54303.
(11) Aimetti, A. A., Feaver, K. R., and Anseth, K. S. (2010) Synthesis
of cyclic, multivalent Arg-Gly-Asp using sequential thiol-ene/thiol-yne
photoreactions. Chem. Commun. (Cambridge, U. K.) 46 (31), 5781−
5783.
(12) Gong, T., Adzima, B. J., and Bowman, C. N. (2013) A novel
copper containing photoinitiator, copper(ii) acylphosphinate, and its
application in both the photomediated CuAAC reaction and in atom
transfer radical polymerization. Chem. Commun. 49 (72), 7950−7952.
(13) Fairbanks, B. D., Sims, E. A., Anseth, K. S., and Bowman, C. N.
(2010) Reaction Rates and Mechanisms for Radical, Photoinitated
Addition of Thiols to Alkynes, and Implications for Thiol−Yne
Photopolymerizations and Click Reactions. Macromolecules 43 (9),
4113−4119.
(14) Pelegri-O’Day, E. M., Lin, E.-W., and Maynard, H. D. (2014)
Therapeutic Protein−Polymer Conjugates: Advancing Beyond PEGy-
lation. J. Am. Chem. Soc. 136 (41), 14323−14332.
(15) van Geel, R., Pruijn, G. J. M., van Delft, F. L., and Boelens, W. C.
(2012) Preventing Thiol-Yne Addition Improves the Specificity of
Strain-Promoted Azide−Alkyne Cycloaddition. Bioconjugate Chem. 23
(3), 392−398.
yne reaction with a cyclooctyne. In all cases, the rebridging was
proven by MS analyses and confirmed by the absence of
1
olefinic proton on H NMR spectra of the resulting products.
Finally, this one-pot reduction thiol−yne methodology was
successfully applied to a Fab fragment of an antibody with a
promising conversion, which set a good ground for the future
syntheses of new protein and antibody conjugates.
ASSOCIATED CONTENT
* Supporting Information
■
S
The Supporting Information is available free of charge on the
Synthesis protocols, experimental details, and additional
characterization data (PDF)
AUTHOR INFORMATION
Corresponding Authors
■
Tel: +49 (0) 721 608 42902.
Notes
The authors declare the following competing financial
interest(s): This work was funded by the Collaborative Post-
Doc Program of Bayer Healthcare.
REFERENCES
■
(1) (a) Flygare, J. A., Pillow, T. H., and Aristoff, P. (2013) Antibody-
drug conjugates for the treatment of cancer. Chem. Biol. Drug Des. 81
(1), 113−21. (b) Jones, L. H., and McKnight, A. J., Eds. (2013)
Biotherapeutics: Recent Developments Using Chemical and Molecular
Biology, Royal Society of Chemistry Drug Discovery Series, Vol 36,
Royal Society of Chemistry.
(2) (a) Veronese, F. M., and Mero, A. (2008) The impact of
PEGylation on biological therapies. BioDrugs 22 (5), 315−29.
(b) Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry
for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54 (4),
459−76.
(3) Miller, L. W., and Cornish, V. W. (2005) Selective chemical
labeling of proteins in living cells. Curr. Opin. Chem. Biol. 9 (1), 56−61.
(4) (a) Garnett, M. C. (2001) Targeted drug conjugates: principles
and progress. Adv. Drug Delivery Rev. 53 (2), 171−216. (b) Wu, A. M.,
and Senter, P. D. (2005) Arming antibodies: prospects and challenges
for immunoconjugates. Nat. Biotechnol. 23 (9), 1137−46. (c) Sapra, P.,
Hooper, A. T., O’Donnell, C. J., and Gerber, H. P. (2011)
Investigational antibody drug conjugates for solid tumors. Expert
Opin. Invest. Drugs 20 (8), 1131−49. (d) Chari, R. V. J., Miller, M. L.,
and Widdison, W. C. (2014) Antibody−Drug Conjugates: An
Emerging Concept in Cancer Therapy. Angew. Chem., Int. Ed. 53
(15), 3796−3827. (e) Klinguer-Hamour, C., Strop, P., Shah, D. K.,
Ducry, L., Xu, A., and Beck, A. (2014) World Antibody-Drug
Conjugate Summit, October 15−16, 2013, San Francisco, CA. mAbs 6
(1), 18−29. (f) Tian, F., Lu, Y., Manibusan, A., Sellers, A., Tran, H.,
Sun, Y., Phuong, T., Barnett, R., Hehli, B., Song, F., DeGuzman, M. J.,
Ensari, S., Pinkstaff, J. K., Sullivan, L. M., Biroc, S. L., Cho, H., Schultz,
P. G., DiJoseph, J., Dougher, M., Ma, D., Dushin, R., Leal, M.,
Tchistiakova, L., Feyfant, E., Gerber, H.-P., and Sapra, P. (2014) A
general approach to site-specific antibody drug conjugates. Proc. Natl.
Acad. Sci. U. S. A. 111 (5), 1766−1771.
(5) Ramil, C. P., and Lin, Q. (2013) Bioorthogonal chemistry:
strategies and recent developments. Chem. Commun. 49 (94), 11007−
11022.
(6) Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., Whiteman, K.
R., Leece, B. A., Kovtun, Y., Goldmacher, V. S., Xie, H., Steeves, R. M.,
Lutz, R. J., Zhao, R., Wang, L., Blattler, W. A., and Chari, R. V. (2006)
G
Bioconjugate Chem. XXXX, XXX, XXX−XXX